LAMIVUDINE/ZIDOVUDINE TABLETS CO-PACKAGED WITH NEVIRAPINE TABLETS

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

58 API Suppliers, 34 USDMF, 16 CEP/COS, 1 JDMF, 10 EU WC, 5 KDMF, 17 NDC API, 23 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

66 Drugs in Development

66 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

438 FDF Dossiers, 128 FDA Orange Book, 128 Europe, 21 Canada, 9 Australia, 118 South Africa, 34 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 600MG BASE;EQ 50MG BASE;300MG, TABLET;ORAL - 150MG;200MG;300MG, TABLET;ORAL - 150MG, TABLET;ORAL - 300MG, TABLET;ORAL - 100MG;300MG;300MG, TABLET;ORAL - 300MG;300MG, TABLET;ORAL - EQ 600MG BASE;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 Rochem International Inc, 17 SPI Pharma, 6 DKSH, 8 Boai NKY Pharmaceuticals Ltd, 5 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 Kirsch Pharma, 1 ACG Worldwide, 8 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 25 BASF, 8 Beneo, 1 Clariant, 10 Corel Pharma Chem, 6 DFE Pharma, 1 Esteem Industries, 2 Finar, 12 Gangwal Chemicals, 5 Ideal Cures, 4 Ingredion Pharma Solutions, 26 Kerry, 2 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 15 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 4 Novo Excipients, 4 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 19 Roquette, 13 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 3 Silverline Chemicals, 2 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

73 Fillers, Diluents & Binders, 48 Coating Systems & Additives, 41 Direct Compression, 35 Disintegrants & Superdisintegrants, 30 Granulation, 30 Thickeners and Stabilizers, 27 Solubilizers, 27 Controlled & Modified Release, 25 Taste Masking, 21 Chewable & Orodispersible Aids, 19 Parenteral, 16 Topical, 15 Co-Processed Excipients, 14 Lubricants & Glidants, 12 Film Formers & Plasticizers, 8 Emulsifying Agents, 7 API Stability Enhancers, 6 Rheology Modifiers, 5 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 1 Stock Recap #PipelineProspector, 104 News #PharmaBuzz

GLOBAL SALES INFORMATION

28 US Medicaid Prescriptions, 33 Regulatory FDF Prices, 35 Annual Reports

MARKET PLACE

15 APIs, 10 FDF Dossiers

PATENTS & EXCLUSIVITIES

20 US Patents, 6 US Exclusivities, 44 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 4 USP, 7 Others

ANALYTICAL

1 BioAnalytical Methods, 1 Analytical Methods

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 205626 / DOSAGE - TABLET;ORAL - 150MG;200MG;300MG

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
LAMIVUDINE(UNII: 2T8Q726O95) (LAMIVUDINE - UNII:2T8Q726O95)	LAMIVUDINE	150mg
NEVIRAPINE(UNII: 99DK7FVK1H) (NEVIRAPINE - UNII:99DK7FVK1H)	NEVIRAPINE	200mg
ZIDOVUDINE(UNII: 4B9XT59T7S) (ZIDOVUDINE - UNII:4B9XT59T7S)	ZIDOVUDINE	300mg

Inactive Ingredients

Ingredient Name	Micro Labs Limited
CELLULOSE, MICROCRYSTALLINE(OP1R32D61U)
HYPROMELLOSE 2910 (5 MPA.S)(R75537T0T4)
LACTOSE MONOHYDRATE(EWQ57Q8I5X)
MAGNESIUM STEARATE(70097M6I30)
POLYETHYLENE GLYCOL 400(B697894SGQ)
POLYSORBATE 80(6OZP39ZG8H)
POVIDONE K25(K0KQV10C35)
SILICON DIOXIDE(ETJ7Z6XBU4)
SODIUM STARCH GLYCOLATE TYPE A POTATO(5856J3G2A2)
TITANIUM DIOXIDE(15FIX9V2JP)

Drug Product Composition: LAMIVUDINE/ZIDOVUDINE TABLETS CO-PACKAGED WITH NEVIRAPINE TABLETS